NBI6024

• CAT Number: I033075
• CAS Number: 239480-61-6
• Molecular Formula: C66H112N20O21
• Molecular Weight: 1521.74
• Purity: 98%
• Synonyms: NBI6024; NBI-6024; NBI 6024
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (5S,8S,14S,17S,20S,23S,26S,29S,32S)-32-((S)-2-((S)-2-((S)-2-((S)-2-amino-3-hydroxypropanamido)-3-(1H-imidazol-4-yl)propanamido)-4-methylpentanamido)-3-methylbutanamido)-8-(2-carboxyethyl)-5-(3-guanidinopropyl)-20,26-diisobutyl-17-isopropyl-14,23,29-trimethyl-4,7,10,13,16,19,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazapentatriacontanedioic acid
• InChI: InChI=1S/C66H112N20O21/c1-30(2)21-43(81-54(96)36(12)75-58(100)42(17-19-49(91)92)80-65(107)52(34(9)10)86-63(105)45(23-32(5)6)84-61(103)46(24-38-25-70-29-74-38)83-56(98)39(67)28-87)60(102)76-37(13)55(97)82-44(22-31(3)4)62(104)85-51(33(7)8)64(106)77-35(11)53(95)72-26-47(88)78-41(16-18-48(89)90)59(101)79-40(15-14-20-71-66(68)69)57(99)73-27-50(93)94/h25,29-37,39-46,51-52,87H,14-24,26-28,67H2,1-13H3,(H,70,74)(H,72,95)(H,73,99)(H,75,100)(H,76,102)(H,77,106)(H,78,88)(H,79,101)(H,80,107)(H,81,96)(H,82,97)(H,83,98)(H,84,103)(H,85,104)(H,86,105)(H,89,90)(H,91,92)(H,93,94)(H4,68,69,71)/t35-,36-,37-,39-,40-,41-,42-,43-,44-,45-,46-,51-,52-/m0/s1Download
• InChIKey: PHEWVCZHSBTZFX-DBCSJUPNSA-N
• SMILES: CC(C[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(NCC(O)=O)=O)CCCNC(N)=N)=O)CCC(O)=O)=O)=O)C)=O)C(C)C)=O)CC(C)C)=O)C)=O)NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@H](CO)N)=O)Cc1nc[nH]c1)=O)CC(C)C)=O)=O)CCC(O)=O)=O)C)=O)C

NBI6024 (Cat No.: I033075) is a synthetic peptide vaccine designed to target autoimmune responses in type 1 diabetes. It is based on an altered peptide ligand derived from the insulin B-chain (B:9-23), aiming to modulate T-cell activity and induce immune tolerance. By selectively downregulating autoreactive T-cells that attack pancreatic beta cells, NBI6024 helps preserve insulin production. It has been evaluated in clinical trials for its potential to delay or prevent disease progression in newly diagnosed type 1 diabetes patients, supporting research in immunotherapy.

Reference

1: Maruyama T. [Pharmacotherapies for type 1 diabetes mellitus]. Nihon Rinsho. 2002 Sep;60 Suppl 9:190-5. Japanese. PMID: 12386992.
2: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Oct;24(8):525-51. PMID: 12500432.
3: Giannoukakis N. NBI-6024 (Neurocrine Biosciences). IDrugs. 2002 Dec;5(12):1162-7. PMID: 12800057.
4: Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, Conlon PJ, Gottlieb PA. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol. 2006 Jan;63(1):59-69. doi: 10.1111/j.1365-3083.2005.01705.x. PMID: 16398702.
5: Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R; NBI-6024 Study Group. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care. 2009 Nov;32(11):2036-40. doi: 10.2337/dc09-0449. Epub 2009 Aug 18. PMID: 19690081; PMCID: PMC2768201.
6: Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, Ling N, Boehme SA, Conlon PJ. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 2002 Jul;51(7):2126-34. doi: 10.2337/diabetes.51.7.2126. PMID: 12086942.